Can You Get Pregnant During Perimenopause?

Why Pregnancy Is Still Possible During Perimenopause

Perimenopause does not switch off ovulation on a fixed schedule. The ovaries keep releasing eggs, just less predictably than in your 20s and 30s. A 2018 analysis in Menopause, using data from the Study of Women's Health Across the Nation (SWAN), found that women in early perimenopause ovulated in roughly 78% of cycles, while women in late perimenopause still ovulated in approximately 39% of cycles [1]. That second figure surprises many people. Close to four in ten late-perimenopausal cycles still carry a real chance of ovulation.

What "Perimenopause" Actually Means Clinically

The STRAW+10 (Stages of Reproductive Aging Workshop) staging system, published in Fertility and Sterility and widely referenced by the American College of Obstetricians and Gynecologists (ACOG), defines the menopausal transition using bleeding pattern changes and hormone trends [2]. Early perimenopause begins when cycle length starts varying by 7 or more days from a woman's usual pattern. Late perimenopause is marked by stretches of 60 or more days without a period before the final one arrives.

Neither stage means infertility. The hormonal variability of perimenopause, driven by erratic follicle-stimulating hormone (FSH) surges and declining ovarian reserve, still produces intermittent ovulatory cycles.

The Hormonal Picture Behind Intermittent Ovulation

FSH rises as ovarian reserve declines, but the rise is not linear. In some cycles, FSH climbs high enough to recruit a follicle that then releases an egg. In others, it falls short. Estradiol swings can also create hormonal conditions that trigger unexpected ovulation, even after 45 or 60 days without a period. This unpredictability is why fertility tracking (calendar methods, cervical mucus, basal body temperature) becomes unreliable during the transition.

Anti-Mullerian hormone (AMH), a marker of remaining egg supply, declines through perimenopause. A 2020 cohort study in Human Reproduction found that women with very low AMH levels tended to reach their final period sooner than women with higher AMH, though the interval varied widely between individuals [3]. The exact sample size and median timeframe reported in that study should be checked against the source before being quoted as a specific number in a published version of this article. The clinically useful point is simpler: a low AMH result does not rule out ovulation or pregnancy in a given cycle, and no single hormone level tells a woman she is done.

How Fertility Changes Across the Perimenopausal Transition

Fertility declines gradually rather than dropping off a cliff. Widely cited maternal-age fertility figures, drawn from ACOG counseling guidance, put natural monthly fecundity (the chance of conceiving in a given cycle) at roughly 5% around age 40, compared with about 20% around age 30 [4]. By age 44, that figure falls to roughly 1 to 2%. Small numbers, but not zero.

Early Perimenopause (Late 30s to Mid-40s)

Cycles are still relatively close together, though variability is starting. Ovulation occurs in most cycles. This is part of why unintended pregnancy in women aged 40 to 44 is more common than many people expect: CDC survey data show that a substantial share of pregnancies in this age group are unintended [5].

Late Perimenopause (Mid to Late 40s)

Cycles become longer and more erratic, with 60- to 90-day gaps common. This can create false reassurance. A woman who has not had a period in three months may assume ovulation has stopped. It may not have. Ovulation can occur at any point during a long cycle, including near its end.

The Post-Period Window That Catches People Off Guard

One scenario causes particular confusion: a woman misses several periods, assumes she has reached menopause, stops contraception, and then either has a spontaneous period or becomes pregnant. This happens because the 12-month rule requires 12 consecutive months of no bleeding. Any bleeding during that window, including light spotting, resets the clock.

Risks Associated With Perimenopausal Pregnancy

Pregnancy during perimenopause carries risks that differ from those in younger women. Understanding them supports decision-making, whether a pregnancy is planned or unintended.

Miscarriage

Chromosomal errors in eggs become more common with age. CDC data indicate a miscarriage rate of approximately 34% of recognized pregnancies at ages 40 to 44, rising to roughly 53% at age 45 and older [5]. These figures largely reflect age-related chromosomal abnormalities in eggs.

Ectopic Pregnancy

Ectopic pregnancy risk rises with age. Any positive pregnancy test in a perimenopausal woman warrants prompt transvaginal ultrasound to confirm the pregnancy is located in the uterus, since ectopic pregnancy is a medical emergency.

Gestational Diabetes and Hypertensive Disorders

A population-based cohort study of pregnancies among women 40 and older found substantially higher rates of gestational diabetes and preeclampsia than in pregnancies among women in their late twenties [6]. The exact percentages in the original study should be verified before being cited as precise figures; the direction and general clinical consensus, that both conditions are more common with advancing maternal age and require closer monitoring, is well established regardless of the exact numbers.

Chromosomal Conditions in the Fetus

Commonly cited maternal-age risk figures put the chance of trisomy 21 (Down syndrome) at roughly 1 in 100 live births at age 40, rising to roughly 1 in 30 at age 45, compared with roughly 1 in 1,500 at age 20 [4]. Prenatal genetic counseling and testing, including cell-free DNA screening and, where indicated, diagnostic testing such as amniocentesis, are standard for pregnancies in this age group.

Contraception During Perimenopause: What Works and What to Avoid

Contraception during perimenopause is not one-size-fits-all. The right choice depends on bleeding pattern, cardiovascular risk, and whether symptom relief is also a goal.

Combined Oral Contraceptives (Low-Dose)

Low-dose combined oral contraceptives (COCs) containing 20 mcg ethinyl estradiol can suppress ovulation reliably and can also reduce hot flashes and regulate irregular bleeding. ACOG Practice Bulletin No. 206 notes that healthy, non-smoking perimenopausal women can use low-dose COCs safely through the menopausal transition [7].

Widely used clinical eligibility guidance classifies combined hormonal contraceptives as generally favorable (benefits outweigh risks) for women 40 and older who do not smoke and have no cardiovascular risk factors, and as less favorable for women who smoke, or who have hypertension, migraine with aura, or a personal history of venous thromboembolism.

Progestin-Only Methods

The progestin-only pill (norethindrone 0.35 mg daily), the hormonal IUD (levonorgestrel 52 mg, marketed as Mirena), and the progestin implant (etonogestrel 68 mg, marketed as Nexplanon) are effective options that avoid the estrogen-related cardiovascular considerations relevant to some older patients. A randomized trial comparing the levonorgestrel IUD with oral medroxyprogesterone for heavy menstrual bleeding found the IUD substantially more effective at reducing blood loss [9]. Heavy or prolonged bleeding is a common complaint in late perimenopause, and this makes the levonorgestrel IUD a reasonable option for patients who need both contraception and bleeding control, though the exact percentage reduction in blood loss varies across studies and should not be quoted as a single fixed number.

Copper IUD

The copper IUD (ParaGard) provides effective, hormone-free contraception for up to 10 years. It suits women who want to avoid hormonal exposure. Its main downside during perimenopause is that it can worsen already heavy or prolonged periods.

Barrier Methods

Condoms, diaphragms, and cervical caps have no systemic effects but require consistent, correct use. Their typical-use failure rates (male condom: approximately 13% per year; diaphragm: approximately 17% per year) are worth discussing openly, since some patients underestimate perimenopausal fertility and use these methods inconsistently as a result [10].

What to Avoid: Relying on FSH Alone

A single serum FSH reading above 30 mIU/mL is sometimes treated informally as proof that a woman "can't get pregnant anymore." That interpretation is not reliable. FSH fluctuates cycle to cycle during perimenopause. The North American Menopause Society's 2022 position statement advises that FSH levels should not be used as a standalone signal that contraception can be stopped [11]. A woman with a high FSH result one month may still ovulate the next.

When Can You Safely Stop Using Contraception?

The general clinical rule: continue contraception until 12 consecutive months have passed without any menstrual bleeding. This applies to women reaching natural menopause.

For women using hormonal contraception, that 12-month window is harder to confirm, because the method itself may suppress bleeding. Common approaches include:

1. Switching to a non-hormonal method around age 50 to 51 and then tracking for 12 months of amenorrhea.
2. Checking FSH on two separate occasions, at least 6 to 8 weeks apart, while off hormonal contraception. Two FSH readings above 30 mIU/mL in a woman over 50 with amenorrhea can support a decision to stop contraception, though NAMS is explicit that this is not a definitive cutoff on its own [11].
3. Consulting a clinician for individualized guidance, particularly if perimenopausal symptoms (night sweats, hot flashes, vaginal dryness) have already prompted a conversation about menopausal hormone therapy (MHT).

For women who have had surgical menopause (bilateral oophorectomy), contraception is no longer needed after the procedure. For women using GnRH agonists such as leuprolide acetate for conditions like endometriosis, ovarian function typically resumes after stopping treatment, so contraception should continue unless surgical menopause has separately been confirmed. This is a situation worth discussing directly with a prescribing clinician rather than assuming.

Perimenopausal Pregnancy: Making an Informed Decision

If a perimenopausal woman discovers she is pregnant, she faces decisions that benefit from prompt medical input and, for many, genetic counseling. Key steps typically include:

• Confirming intrauterine location with transvaginal ultrasound once the test is positive.
• Establishing care with a maternal-fetal medicine (MFM) specialist given the higher-risk profile.
• Discussing chromosomal screening options, including cell-free DNA (cfDNA) testing starting around 10 weeks and diagnostic testing such as amniocentesis if indicated.
• Reviewing current medications for risk to a pregnancy. Women on MHT or hormonal contraception who continue a pregnancy should stop these under clinician guidance.
• Planning for glucose tolerance testing, blood pressure monitoring, and fetal growth surveillance throughout pregnancy.

For women who do not wish to continue a pregnancy, the FDA-approved medication abortion regimen (mifepristone followed by misoprostol) is approved for use through 70 days of gestation (10 weeks from the last menstrual period) and has a high reported success rate in FDA labeling and approval materials [12][14]. Procedural options, such as aspiration or dilation and evacuation, are also available depending on gestational age and clinical setting. Exact efficacy figures and dosing belong to a clinician conversation, not a general information page, since they depend on gestational age and individual clinical factors.

Perimenopause, Pregnancy, and Hormone Therapy: Sorting Out the Overlap

This area causes real confusion. Women in perimenopause who start menopausal hormone therapy (MHT) for symptom relief, typically low-dose estradiol plus a progestogen, are not protected from pregnancy by MHT. Standard MHT doses are too low to reliably suppress ovulation.

A Decision Framework for Sorting Out Contraception, Symptoms, and MHT

This is not a diagnostic tool. It is a starting structure for the conversation a perimenopausal patient should have with her own clinician, built around the few facts that actually change the recommendation.

The facts that drive the decision:

• Any bleeding, however irregular, means menopause is not yet confirmed.
• Only 12 consecutive months of zero bleeding count. One spot resets the clock.
• Standard MHT does not prevent pregnancy, even though it treats similar symptoms.
• A single FSH result, high or low, does not settle the question.

Step 1: Is there any menstrual bleeding, even irregular spotting? If yes, she is not in confirmed menopause and needs contraception if she is sexually active and does not want to be pregnant.

Step 2: Does she also want relief from hot flashes, night sweats, or bleeding irregularity? If yes, a low-dose COC (20 mcg ethinyl estradiol) can address contraception and symptoms together, but only for non-smoking women without cardiovascular risk factors.

Step 3: Does she have a contraindication to estrogen? History of venous thromboembolism, migraine with aura, active smoking after age 35, or uncontrolled hypertension point toward a progestin-only pill, an IUD (hormonal or copper), or a barrier method instead.

Step 4: Has she completed 12 consecutive months without any bleeding? If yes, contraception can typically be stopped, and standard MHT dosing can start if symptoms warrant it, with a progestogen added for anyone with an intact uterus.

Exceptions that override the steps above:

• Surgical menopause (both ovaries removed): contraception is not needed regardless of bleeding history.
• Recent use of a GnRH agonist (such as leuprolide): ovarian function, and fertility, may return after stopping. Do not assume amenorrhea during treatment equals menopause.
• Hormonal contraception itself often suppresses bleeding, which makes the 12-month count unreliable while still on the method. This needs a specific plan with a clinician (switching methods, or paired FSH testing) rather than watching the calendar alone.

What this framework cannot tell you: whether a specific method is safe given a specific patient's full medical history, or whether a specific missed period is menopause versus pregnancy versus something else. Those require an individualized clinical assessment.

Recognizing Perimenopausal Symptoms Versus Pregnancy Symptoms

Perimenopause and early pregnancy share several symptoms, which can delay recognizing a pregnancy in this age group. Overlapping symptoms include nausea, breast tenderness, fatigue, mood changes, and missed periods.

Features that point toward pregnancy rather than perimenopause:

• A positive urine hCG test. This is the definitive first step. Home tests typically detect hCG at approximately 20 to 25 mIU/mL, which is usually reliable from the day of a missed period.
• Rising hCG on serial blood tests, which in a normally developing early pregnancy tends to roughly double every 48 to 72 hours.
• A gestational sac visible on transvaginal ultrasound.

Women who assume nausea and a missed period are just perimenopause, without taking a pregnancy test, can delay care for weeks. Any missed period in a perimenopausal woman who is sexually active and not using reliable contraception is worth checking with a pregnancy test.

What the Data Say About Unintended Pregnancy in This Age Group

Perimenopausal unintended pregnancy is not rare. CDC data show that unintended pregnancy continues at meaningful rates through the early-to-mid 40s, even though it is proportionally less common than in younger age groups [5][13]. A frequently cited Guttmacher Institute analysis puts a specific rate for women 40 to 44 higher than the rate for women 30 to 34; that specific figure should be confirmed directly against the Guttmacher publication before being republished, since the CDC page linked here is a general overview rather than the original analysis [13].

A meaningful contributor is contraceptive discontinuation. Women who experienced years of difficulty conceiving in their late 30s, or who simply assume perimenopause means infertility, often stop contraception before the 12-month amenorrhea threshold has been met. Consistent counseling about this specific risk during well-woman visits in the 40s is an area where practice varies.

Talking to Your Clinician: Key Questions to Bring to Your Appointment

Direct questions help patients get actionable answers at gynecology and primary care visits:

• "Based on my bleeding pattern, do I still need contraception?"
• "Which contraceptive method would also help with my hot flashes or heavy bleeding?"
• "If I start hormone therapy for menopause symptoms, does that protect me from pregnancy?"
• "My FSH came back high. Does that mean I can stop using birth control?"
• "How will I know when it's actually safe to stop contraception?"
• "If I got pregnant now, what risks would I face?"

Bringing a list of current medications and a record of the last 6 to 12 menstrual periods (dates and flow) to the appointment gives the clinician concrete information to individualize recommendations.

NAMS's 2022 position statement supports counseling perimenopausal patients proactively about the ongoing need for contraception until 12 months of amenorrhea confirm menopause, rather than waiting for the patient to raise the topic [11].